We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a blow to the biosimilars industry, the federal appellate court has reiterated its position that biosimilars makers must give reference product holders six months’ notice before going to market. Read More
Horizon Therapeutics has filed suit against Par Pharmaceutical, alleging infringement of three patents for its urea cycle disorders drug Ravicti. Read More
Medical products companies spent $7.52 billion on physicians and teaching hospitals in 2015, roughly in line with 2014 results, according to the Centers for Medicare & Medicaid Services. Read More
The FDA is breaking down how drugmakers should comply with standards established by the International Council for Harmonization and the United States Pharmacopeia for controlling elemental impurities. Read More